Clarity Pharmaceuticals Ltd
ASX:CU6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
AU |
|
Indofood Sukses Makmur Tbk PT
OTC:PIFMF
|
ID |
|
V2 Retail Ltd
NSE:V2RETAIL
|
IN |
|
GI Engineering Solutions Ltd
NSE:GISOLUTION
|
IN |
|
E
|
Euro Cervantes SOCIMI SA
MAD:YEUR
|
ES |
|
Good Natured Products Inc
XTSX:GDNP
|
CA |
|
Smartfit Escola de Ginastica e Danca SA
BOVESPA:SMFT3
|
BR |
|
F
|
Fine Metal Technologies PCL
SET:FMT
|
TH |
|
C
|
Chemical Industries (Far East) Ltd
SGX:C05
|
SG |
|
F
|
FN Republic Co Ltd
KOSDAQ:064090
|
KR |
|
A
|
Adecco Group AG
LSE:0QNM
|
CH |
|
M
|
Mercury Corp
KOSDAQ:100590
|
KR |
|
B
|
Biotest AG
XETRA:BIO2
|
DE |
|
Beijer Alma AB
STO:BEIA B
|
SE |
|
Storskogen Group AB (publ)
STO:STOR B
|
SE |
Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd. engages in the development of radiopharmaceutical products focused on the treatment of serious diseases. The firm is focused on developing products to address the growing need for radiopharmaceuticals in oncology. Its has a diverse range of products in clinical trials which address both large indications such as prostate cancer and breast cancer, as well as rare and orphan indications such as neuroendocrine tumours (NETs) and neuroblastoma of cancer. The SAR Technology platform is the Company’s platform. Its pipeline of products in clinical and preclinical stages include SARTATE, SAR-Bombesin and SAR-bisPSMA. Its SARTATE is for the treatment of neuroblastoma, and for the diagnosis of NETs. Its SAR-Bombesin is a pan-cancer treatment product, including for the treatment of breast cancer and prostate cancer. Its SAR-bisPSMA is for the treatment of prostate cancer, and for the diagnosis of prostate cancer.
Clarity Pharmaceuticals Ltd. engages in the development of radiopharmaceutical products focused on the treatment of serious diseases. The firm is focused on developing products to address the growing need for radiopharmaceuticals in oncology. Its has a diverse range of products in clinical trials which address both large indications such as prostate cancer and breast cancer, as well as rare and orphan indications such as neuroendocrine tumours (NETs) and neuroblastoma of cancer. The SAR Technology platform is the Company’s platform. Its pipeline of products in clinical and preclinical stages include SARTATE, SAR-Bombesin and SAR-bisPSMA. Its SARTATE is for the treatment of neuroblastoma, and for the diagnosis of NETs. Its SAR-Bombesin is a pan-cancer treatment product, including for the treatment of breast cancer and prostate cancer. Its SAR-bisPSMA is for the treatment of prostate cancer, and for the diagnosis of prostate cancer.
